BETA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
India's Beta Drugs jumps after regulatory milestones in Azerbaijan, Philippines
** Shares of Beta Drugs Ltd BTAD.NS rise as much as 6.8% to 1,405 rupees
** Co's manufacturing facility inspected by Ministry of Health of Azerbaijan Republic, co expects to receive good manufacturing practices approval within next one to two months
** Adds, gets certificates of product registration for 2 brands in Philippines
** Stock on track to snap 5 days of losses
** BTAD last up 2.5%, cutting YTD losses to 15%
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
** Shares of Beta Drugs Ltd BTAD.NS rise as much as 6.8% to 1,405 rupees
** Co's manufacturing facility inspected by Ministry of Health of Azerbaijan Republic, co expects to receive good manufacturing practices approval within next one to two months
** Adds, gets certificates of product registration for 2 brands in Philippines
** Stock on track to snap 5 days of losses
** BTAD last up 2.5%, cutting YTD losses to 15%
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
Beta Drugs To Buy 66.09% Of Nivian Life Sciences For 694 MLN Rupees
Jan 9 (Reuters) - Beta Drugs Ltd BTAD.NS:
TO BUY 66.09% OF EQUITY SHARE CAPITAL IN NIVIAN LIFE SCIENCES FOR 694 MILLION RUPEES
Further company coverage: BTAD.NS
(([email protected];))
Jan 9 (Reuters) - Beta Drugs Ltd BTAD.NS:
TO BUY 66.09% OF EQUITY SHARE CAPITAL IN NIVIAN LIFE SCIENCES FOR 694 MILLION RUPEES
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs Receives Dcgi Approval For Methotrexate Oral Solution
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
RECEIVES DCGI APPROVAL FOR METHOTREXATE ORAL SOLUTION
Source text: ID:nNSE4L8P0Y
Further company coverage: BTAD.NS
(([email protected];))
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
RECEIVES DCGI APPROVAL FOR METHOTREXATE ORAL SOLUTION
Source text: ID:nNSE4L8P0Y
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs To Consider Raising Of Funds
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
BETA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nNSE3QJk0Q
Further company coverage: BTAD.NS
(([email protected];))
Oct 16 (Reuters) - Beta Drugs Ltd BTAD.NS:
BETA DRUGS LTD - TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nNSE3QJk0Q
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs To Write Off Investment Made Amounting $88,000 In Beta Ubk. International
Nov 7 (Reuters) - Beta Drugs Ltd BTAD.NS:
APPROVED TO WRITE OFF INVESTMENT MADE BY CO AMOUNTING 88,000 US DOLLARS IN BETA UBK. INTERNATIONAL
Source text for Eikon: ID:nNSE5ccL40
Further company coverage: BTAD.NS
(([email protected];))
Nov 7 (Reuters) - Beta Drugs Ltd BTAD.NS:
APPROVED TO WRITE OFF INVESTMENT MADE BY CO AMOUNTING 88,000 US DOLLARS IN BETA UBK. INTERNATIONAL
Source text for Eikon: ID:nNSE5ccL40
Further company coverage: BTAD.NS
(([email protected];))
Beta Drugs's Baddi Oncology Manufacturing Plant Receives ANVISA Approval
April 20 (Reuters) - Beta Drugs Ltd BTAD.NS:
CO'S ONCOLOGY MANUFACTURING PLANT RECEIVES ANVISA APPROVAL
ANVISA NOD FOR ORAL SOLIDS, INJECTABLES FORMULATIONS
Source text for Eikon: ID:nNSE1PWMP4
Further company coverage: BTAD.NS
(([email protected];))
April 20 (Reuters) - Beta Drugs Ltd BTAD.NS:
CO'S ONCOLOGY MANUFACTURING PLANT RECEIVES ANVISA APPROVAL
ANVISA NOD FOR ORAL SOLIDS, INJECTABLES FORMULATIONS
Source text for Eikon: ID:nNSE1PWMP4
Further company coverage: BTAD.NS
(([email protected];))
Events:
Bonus
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Beta Drugs do?
Beta Drugs, a part of Adley Group, specializes in manufacturing oncology products like anti-cancer tablets, capsules, injections, and lyophilized injections. With a portfolio of over 50 products, it caters to the treatment of various cancer diseases.
Who are the competitors of Beta Drugs?
Beta Drugs major competitors are Ind-Swift Lab., Sakar Healthcare, Wanbury, Venus Remedies, Bharat Parenterals, Fredun Pharma, Anuh Pharma. Market Cap of Beta Drugs is ₹1,068 Crs. While the median market cap of its peers are ₹1,198 Crs.
Is Beta Drugs financially stable compared to its competitors?
Beta Drugs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Beta Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Beta Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Beta Drugs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Beta Drugs balance sheet?
Balance sheet of Beta Drugs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Beta Drugs improving?
The profit is oscillating. The profit of Beta Drugs is ₹17.46 Crs for TTM, ₹42.42 Crs for Mar 2025 and ₹36.44 Crs for Mar 2024.
Is the debt of Beta Drugs increasing or decreasing?
Yes, The net debt of Beta Drugs is increasing. Latest net debt of Beta Drugs is ₹23.19 Crs as of Sep-25. This is greater than Mar-25 when it was -₹155.7 Crs.
Is Beta Drugs stock expensive?
Beta Drugs is not expensive. Latest PE of Beta Drugs is 25.18, while 3 year average PE is 41.96. Also latest EV/EBITDA of Beta Drugs is 9.44 while 3yr average is 16.74.
Has the share price of Beta Drugs grown faster than its competition?
Beta Drugs has given better returns compared to its competitors. Beta Drugs has grown at ~44.8% over the last 7yrs while peers have grown at a median rate of 26.15%
Is the promoter bullish about Beta Drugs?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Beta Drugs is 64.63% and last quarter promoter holding is 64.9%
Are mutual funds buying/selling Beta Drugs?
There is Insufficient data to gauge this.